JP5622775B2 - Composition for treating dermatosis, formulation using the same, and preparation method thereof - Google Patents

Composition for treating dermatosis, formulation using the same, and preparation method thereof Download PDF

Info

Publication number
JP5622775B2
JP5622775B2 JP2012064489A JP2012064489A JP5622775B2 JP 5622775 B2 JP5622775 B2 JP 5622775B2 JP 2012064489 A JP2012064489 A JP 2012064489A JP 2012064489 A JP2012064489 A JP 2012064489A JP 5622775 B2 JP5622775 B2 JP 5622775B2
Authority
JP
Japan
Prior art keywords
vitamin
composition
acne
skin
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012064489A
Other languages
Japanese (ja)
Other versions
JP2012197276A (en
Inventor
シンタク ウォン
シンタク ウォン
Original Assignee
シンタク ウォン
シンタク ウォン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シンタク ウォン, シンタク ウォン filed Critical シンタク ウォン
Publication of JP2012197276A publication Critical patent/JP2012197276A/en
Application granted granted Critical
Publication of JP5622775B2 publication Critical patent/JP5622775B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07Retinol compounds, e.g. vitamin A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4172Imidazole-alkanecarboxylic acids, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Description

本発明は、皮膚用化粧品又は医薬品分野に属するものであり、具体的には、皮膚病の改善と治療のため、直接使用したり化粧品又は医薬品製剤の形態で皮膚の一部に使用したりする皮膚病の治療用組成物に関する。さらに、それを用いた製剤及びその調制法に関する。   The present invention belongs to the field of cosmetics for skin or medicine, and specifically, it is used directly for the improvement and treatment of dermatoses or used on a part of skin in the form of cosmetics or medicines. The present invention relates to a composition for treating skin diseases. Furthermore, it is related with the formulation using the same and its control method.

現在、社会の発展と人々の生活水準の向上に伴い、生活の質を追求し、体の健康及び皮膚の健康・美しさに関する意識も段々強くなってきているため、様々な新しい化粧品が次々と市場に出回っている。現在、国内外の化粧品は以下のような問題があり、即ち、皮膚の生理状態を根本から変えない保湿機能だけを持つ化粧品が多く、そして、一部の化粧品は、精製・加工の費用が高いが、原料が変質しやすかったり異臭がしたりすることが多いので、特別な防腐剤等の化学成分を使用する必要があり、このように衛生基準を満たさない場合が多いため、皮膚に良くないと同時に皮膚に傷害を与える。本製品は、主に、天然酸化防止剤を用いることによって製品の変質を防止する。   At present, with the development of society and the improvement of people's living standards, the pursuit of quality of life and the awareness of body health and skin health / beauty are getting stronger, so various new cosmetics are being introduced one after another. It is on the market. Currently, domestic and foreign cosmetics have the following problems: many cosmetics have only a moisturizing function that does not fundamentally change the physiological state of the skin, and some cosmetics are expensive to refine and process However, since the raw materials are likely to be altered or have a strange odor, it is necessary to use chemical components such as special preservatives. At the same time, it damages the skin. This product mainly prevents the product from being altered by using natural antioxidants.

人の体の最外層保護層として外部環境に対抗する皮膚は、代謝欠陥、外力による摩擦又は圧迫及び細菌侵入などがある場合に、保護本能から表皮が増殖してそれに対抗するため、うろこ状の増殖(乾癬)、たこ、亀裂状の増殖(手足白癬)、鶏眼などの皮膚病変を生じる。人体細胞は、例えば、人体必須の不飽和脂肪酸や必須のアミノ酸など栄養成分を多く摂取しなければならない。人体は様々なルートでこれらの栄養成分を吸収利用し、外部環境に対抗する第一障壁として皮膚の細胞にまで輸送する。栄養成分が不足すると、免疫力低下による皮膚細胞の老化又は病変が起こる。   The skin that opposes the external environment as the outermost protective layer of the human body has a scaly shape because the epidermis proliferates against the instinct in the case of metabolic defects, friction or compression by external forces, and bacterial invasion. Causes skin lesions such as proliferation (psoriasis), octopus, crack-like proliferation (crested limbs), and chicken eyes. Human body cells must ingest many nutrient components such as, for example, unsaturated fatty acids essential to the human body and essential amino acids. The human body absorbs and uses these nutrients through various routes and transports them to skin cells as a primary barrier against the external environment. Insufficient nutritional components cause skin cell aging or lesions due to reduced immunity.

臨床実践や日常生活では、上記の皮膚病症を患う多数の患者は、皮膚表層病変が出る時、これを改善するために医薬品又は化粧品を用いたが、逆に不当な使用によって皮膚内部の水分と皮脂のバランスが崩れる。それに、長期的にはこのような医薬品又は化粧品を使用すると、皮膚の皮脂腺をフィードバック刺激し分泌を異常にするとともに、皮膚が外界からの刺激に対してさらに敏感になるので、皮膚が破裂、増殖したり、皮膚に斑や膿瘍を生じたりする。   In clinical practice and daily life, many patients suffering from the above-mentioned dermatoses have used medicines or cosmetics to improve the skin surface lesions, but conversely, due to inappropriate use, The balance of sebum is lost. In addition, when such drugs or cosmetics are used over the long term, the skin sebaceous glands are stimulated with feedback and abnormal secretion, and the skin becomes more sensitive to external stimuli, causing the skin to rupture and proliferate. Or cause spots or abscesses on the skin.

開示された特許文献を検索したところ、皮膚疾病の治療に関する特許はいずれも刺激的な成分を含むことを見出した。臨床使用の経験から、長期にこのような医薬品又は化粧品を使用すると、皮膚の薬剤耐性と刺激性が強まり、皮膚の自己修復力が低下し、より多くの副作用が起こることが分かった。   Searching the disclosed patent literature, it was found that all patents relating to the treatment of skin diseases contain stimulating ingredients. Clinical experience has shown that long-term use of such drugs or cosmetics increases skin drug resistance and irritation, reduces skin self-healing power, and causes more side effects.

そのため、皮膚に刺激しない且つ皮膚病の治療又は予防、皮膚老化の遅延や皮膚機能の修復などの効果がある外用皮膚製剤の開発が必要である。   Therefore, it is necessary to develop an external skin preparation that does not irritate the skin and has effects such as treatment or prevention of skin diseases, delay of skin aging and restoration of skin function.

本発明の目的は、皮膚を刺激しないで且つ直接使用したり、化粧品又は医薬製剤の形態で皮膚の一部に使用したりする可能性がある、皮膚関連疾病の予防、改善又は治療及び皮膚機能の修復に用いる組成物、並びにそれからなる製剤及びその調製方法を提供することである。   The object of the present invention is to prevent, ameliorate or treat skin-related diseases and skin functions that do not irritate the skin and can be used directly or on a part of the skin in the form of a cosmetic or pharmaceutical preparation It is intended to provide a composition for use in the repair of a drug, a preparation comprising the same, and a method for preparing the same.

本発明は、不飽和脂肪酸、コラーゲン、アミノ酸、ビタミン及び無機塩を含有する皮膚病の治療用組成物を提供する。その中、上記不飽和脂肪酸は、オレイン酸、リノール酸、リノレン酸、アラキドン酸などの人体必須の不飽和脂肪酸から選ばれる一種以上であってもよい。本発明で使用した不飽和脂肪酸は精製後の植物性不飽和脂肪酸が好ましく、精製工程は可溶化処理、超臨界流体抽出、超音波抽出などの方法を使用できる。植物性不飽和脂肪酸の原料は、例えばオリーブ油、菜種油、ひまわり油、茶油などの各種類の植物油を用いても良い。コラーゲンは、一種の蛋白の総称であり、魚、豚、牛といった動物性原料から抽出するものであってもよい。コラーゲンは、バイオ−テクノロジーによって抽出したコラーゲンであってもよく、あるいは化学抽出法によって抽出したコラーゲンであってもよい。上記アミノ酸は、一種以上の人体必須のアミノ酸であり、その中では、人体必須のアミノ酸とは、リジン、トリプトファン、フェニルアラニン、メチオニン、スレオニン、イソロイシン、ロイシン、バリンなどの8種のアミノ酸を意味するが、ヒスチジン、アルギニンを含んでもよい。上記ビタミンとして、ビタミンE及び/又はビタミンAが好ましい。上記無機塩として、ナトリウム塩及び/又はカリウム塩が好ましい。   The present invention provides a composition for the treatment of skin diseases containing unsaturated fatty acids, collagen, amino acids, vitamins and inorganic salts. Among them, the unsaturated fatty acid may be one or more selected from unsaturated fatty acids essential to the human body such as oleic acid, linoleic acid, linolenic acid, and arachidonic acid. The unsaturated fatty acid used in the present invention is preferably a vegetable unsaturated fatty acid after purification, and a method such as solubilization, supercritical fluid extraction, or ultrasonic extraction can be used for the purification step. As the raw material of the vegetable unsaturated fatty acid, for example, various types of vegetable oils such as olive oil, rapeseed oil, sunflower oil and tea oil may be used. Collagen is a general term for a kind of protein, and may be extracted from animal raw materials such as fish, pigs and cows. The collagen may be collagen extracted by biotechnology, or may be collagen extracted by a chemical extraction method. The amino acids are one or more essential amino acids in the human body. Among them, the essential amino acids include eight amino acids such as lysine, tryptophan, phenylalanine, methionine, threonine, isoleucine, leucine, and valine. , Histidine, and arginine. As said vitamin, vitamin E and / or vitamin A are preferable. As the inorganic salt, a sodium salt and / or a potassium salt is preferable.

上記組成物の中、重量%で、不飽和脂肪酸の含有量が65%〜90%であり、他の成分の含有量については、コラーゲンが0.1%〜15%、アミノ酸が0.1%〜10%、ビタミンが0.1%〜10%、及び無機塩が0.05%〜1%とする。ここで、不飽和脂肪酸は、オレイン酸、リノール酸、リノレン酸、アラキドン酸などからなる群から選ばれる一種以上であってもよく、多種の不飽和脂肪酸を異なる割合で混合することができる。アミノ酸は人体必須のアミノ酸のうちの一種以上であってもよく、アミノ酸の種類の選択及びその組成割合は、具体の状況に応じて決められる。ビタミンとしては、ビタミンE及びビタミンAが好ましく、その含有量は、ビタミンEが0.1%〜1%、ビタミンAが0.1%〜1%であることが好ましい。無機塩としては、ナトリウム塩及びカリウム塩が好ましく、その含有量は、ナトリウム塩が0.05%〜0.9%、カリウム塩が0.05%〜0.1%であることが好ましい。その中でも、ナトリウム塩は塩化ナトリウムの形態で、カリウム塩は塩化カリウムの形態で存在しても良い。   In the above composition, the content of unsaturated fatty acid is 65% to 90% by weight, and the content of other components is 0.1% to 15% for collagen and 0.1% for amino acid. -10%, vitamins 0.1% to 10%, and inorganic salts 0.05% to 1%. Here, the unsaturated fatty acid may be one or more selected from the group consisting of oleic acid, linoleic acid, linolenic acid, arachidonic acid, and the like, and various unsaturated fatty acids can be mixed at different ratios. The amino acid may be one or more of amino acids essential for the human body, and the selection of the type of amino acid and the composition ratio thereof are determined according to the specific situation. As vitamins, vitamin E and vitamin A are preferable, and the contents thereof are preferably 0.1% to 1% for vitamin E and 0.1% to 1% for vitamin A. As the inorganic salt, sodium salt and potassium salt are preferable, and the content is preferably 0.05% to 0.9% for sodium salt and 0.05% to 0.1% for potassium salt. Among them, the sodium salt may exist in the form of sodium chloride, and the potassium salt may exist in the form of potassium chloride.

本発明はさらに、上記組成物の中に賦形剤を添加することにより使用に適する様々な剤形に調製される上記組成物が含まれる製剤を提供する。例えば、薬学上許容されるクリーム状にできる賦形剤を加えて軟膏剤を調製してもよく、そして、需要に応じて薬学上許容される界面活性剤にて製剤の効果をさらに改善してもよく、又は、薬学上許容される液状にできる賦形剤を加えることで、液剤、スプレー剤、及び上記製剤をさらに加工して製造されるマスクを作っても良い。なお、本発明の組成物をより便利に使用するために製剤を調製するが、具体な臨床応用現場において、本発明の組成物の中へ賦形剤(及び/又は界面活性剤)と香料を加えることなく、そのまま患者の皮膚の患部に塗っても良い。   The present invention further provides formulations comprising the composition prepared in various dosage forms suitable for use by adding excipients to the composition. For example, an ointment may be prepared by adding pharmaceutically acceptable excipients that can be creamed, and the efficacy of the formulation can be further improved with pharmaceutically acceptable surfactants as required. Alternatively, by adding an excipient that can be made into a pharmaceutically acceptable liquid, a mask prepared by further processing the liquid, the spray, and the above preparation may be prepared. In addition, although a formulation is prepared in order to use the composition of this invention more conveniently, an excipient | filler (and / or surfactant) and a fragrance | flavor are put into the composition of this invention in the concrete clinical application field. You may apply to the affected part of a patient's skin as it is, without adding.

上記製剤における各成分の含有量は、不飽和脂肪酸が50%〜70%、コラーゲンが0.1%〜10%、アミノ酸が0.1%〜6%、ビタミンが0.1%〜7%、無機塩が0.05%〜1%、賦形剤が10%〜25%、及び植物性香料が1%〜5%である。その中で、ビタミンとしては0.1%〜1%のビタミンEと0.1%〜1%のビタミンAが好ましい。無機塩としては、0.05%〜0.9%のナトリウム塩と0.05%〜0.1%のカリウム塩が好ましい。賦形剤は、薬学的に許容される各種類の補助薬又は界面活性剤であってもよく、又は需要に応じて天然植物性香料を含んでも良い。   The content of each component in the preparation is 50% to 70% of unsaturated fatty acid, 0.1% to 10% of collagen, 0.1% to 6% of amino acid, 0.1% to 7% of vitamin, The inorganic salt is 0.05% to 1%, the excipient is 10% to 25%, and the vegetable flavor is 1% to 5%. Among them, 0.1% to 1% vitamin E and 0.1% to 1% vitamin A are preferable as vitamins. As the inorganic salt, 0.05% to 0.9% sodium salt and 0.05% to 0.1% potassium salt are preferable. The excipient may be each type of pharmaceutically acceptable adjuvant or surfactant, or may include natural vegetable flavors as required.

本発明はさらに、以下のステップを含む上記製剤の調製方法を提供する。
(1)上記製剤の組成に従って原料を取る、
(2)コラーゲンおよび水溶性原料を溶解させて水溶性ゲルマトリックスを得る。ここで、水溶性原料はアミノ酸、ビタミン及び無機塩である、
(3)不飽和脂肪酸中に賦形剤と適量の界面活性剤を加え、均一に混合させた後、ステップ(2)で得られた水溶性ゲルマトリックスを徐々に加え、均一に乳化させることにより、軟膏剤又は液剤を得る、
(4)最終製品に仕上げて包装する。
The present invention further provides a method for preparing the above preparation comprising the following steps.
(1) Taking raw materials according to the composition of the above preparation,
(2) A collagen and a water-soluble raw material are dissolved to obtain a water-soluble gel matrix. Here, the water-soluble raw materials are amino acids, vitamins and inorganic salts,
(3) After adding an excipient and an appropriate amount of a surfactant to the unsaturated fatty acid and mixing them uniformly, the water-soluble gel matrix obtained in step (2) is gradually added and uniformly emulsified. Obtain an ointment or solution,
(4) Finish the final product and package it.

ここで、不飽和脂肪酸は、オレイン酸、リノール酸、リノレン酸、アラキドン酸などからなる群から選ばれる一種以上であってもよく、植物不飽和脂肪酸から抽出したものである。精製工程は可溶化処理、超臨界流体抽出、超音波抽出などの方法を採用しても良いが、植物不飽和脂肪酸を凝結させてから高速遠心して不飽和脂肪酸を精製する方法が好ましく、この方法は、飽和脂肪酸と不飽和脂肪酸の凝固点の相違を利用して分離と精製を行う。植物不飽和脂肪酸の原料は、オリーブ油、菜種油、ひまわり油、茶油など各種類の植物油を用いても良い。コラーゲンは、バイオ−テクノロジーによって抽出したコラーゲンであってもよく、あるいは化学抽出法によって抽出したコラーゲンであってもよい。   Here, the unsaturated fatty acid may be one or more selected from the group consisting of oleic acid, linoleic acid, linolenic acid, arachidonic acid, and the like, and is extracted from a plant unsaturated fatty acid. The purification step may employ methods such as solubilization, supercritical fluid extraction, and ultrasonic extraction, but a method of purifying unsaturated fatty acids by condensing plant unsaturated fatty acids and then performing high-speed centrifugation is preferred. Uses the difference in freezing point between saturated and unsaturated fatty acids for separation and purification. As the raw material of the plant unsaturated fatty acid, various types of vegetable oils such as olive oil, rapeseed oil, sunflower oil, tea oil may be used. The collagen may be collagen extracted by biotechnology, or may be collagen extracted by a chemical extraction method.

本発明に係る組成物は直接に皮膚に使用したり、化粧品又は医薬製剤の形態で皮膚の一部に使用したりしてもよい。上記製剤は、皮膚用の各種剤形であってもよく、例えば、軟膏剤、液剤、スプレー剤などが挙げられる。それに、他の材料と組み合わせてもよく、例えば、軟膏状又は液状のものを単層の薄膜状の下地に塗布し、マスクに加工した後パッケージする。上記薄膜状下地は純綿、不織布又は合成繊維材料を用いる。   The composition according to the present invention may be used directly on the skin, or may be used on a part of the skin in the form of a cosmetic or pharmaceutical preparation. The above preparation may be various skin dosage forms, and examples thereof include an ointment, a liquid, and a spray. In addition, it may be combined with other materials. For example, an ointment or liquid is applied to a single-layer thin film base, processed into a mask, and then packaged. The thin film base is made of pure cotton, non-woven fabric or synthetic fiber material.

以下、本発明に係る組成物の薬理分析を行う。本発明の組成物における成分は、いずれも人体必須の栄養成分であり,且つ多数は外界から補充しなければならない。全ての組成成分は、食べられる安全性が高いものである。すべての栄養成分は、体循環を要せずそのまま経皮吸収され皮膚細胞まで供給されるため、皮膚細胞の栄養を保証し、免疫力を向上させ、皮膚に自身の能力を回復させ、細菌の侵入とウイルスの侵害に抵抗する。   Hereinafter, pharmacological analysis of the composition according to the present invention is performed. All the components in the composition of the present invention are essential nutrients for the human body, and many of them must be supplemented from the outside world. All the ingredients are safe to eat. All nutritional components are absorbed through the skin and supplied to the skin cells without the need for systemic circulation, ensuring the nutrition of the skin cells, improving immunity, restoring their own ability to the skin, Resist intrusion and virus infringement.

漢方医学の皮膚浸透圧療法の学説に基づき、本製品は、活性栄養物質と栄養成分に富み、すぐに皮膚に浸透し皮膚細胞に欠けた栄養を迅速に補充できるので、細胞の再生機能の強化、毛穴を閉塞する角質層や重金属や化学汚染物の除去、毛穴の縮小ができるうえに、にきび、膿疱、せつ腫や皮膚表面の潰瘍などの病症の治療に寄与している。   Based on the Chinese medicine skin osmotic therapy theory, this product is rich in active nutrients and nutrients, and can quickly penetrate the skin and quickly replenish the nutrients lacking skin cells, enhancing the cell's regenerative function In addition to removing stratum corneum, heavy metals and chemical contaminants that block pores, and reducing pore size, it also contributes to the treatment of diseases such as acne, pustules, cysts and ulcers on the skin surface.

本発明に係る製品によれば、皮膚に必要な栄養を補充し、皮膚の微小循環を改善し、細胞自身の免疫力を向上させ、皮膚の成長と修復に必要な正常な生理的要素を維持し、皮膚組織の正常な形態と機能を維持し、外界からの侵害に抵抗する自身の能力を高め、皮膚組織表層の健康を保持することができる。   The product according to the present invention supplements the skin with the necessary nutrients, improves the microcirculation of the skin, improves the immunity of the cells themselves, and maintains the normal physiological elements necessary for skin growth and repair In addition, the normal form and function of the skin tissue can be maintained, the ability of the skin tissue to resist the invasion from the outside world can be enhanced, and the health of the skin tissue surface can be maintained.

本発明に係る組成物及びそれを用いた製剤は、臨床実験における効果が顕著であり、また、神経皮膚炎(乾癬)、にきび、手足白癬、爪白癬、鶏眼、爪囲炎等の皮膚病への効果が即時に現れる。   The composition according to the present invention and a preparation using the composition have remarkable effects in clinical experiments, and also have skin diseases such as neurodermatitis (psoriasis), acne, tinea pedis, onychomycosis, chicken eye, and onychomyelitis. Immediate effects appear.

以下、実施例を示して本発明をさらに説明する。以下の実施例は当業者に本発明をさらに理解させるものであるが、本発明はこれらの実施例に何ら限定されるものではない。   Hereinafter, the present invention will be further described with reference to examples. The following examples are intended to allow those skilled in the art to further understand the present invention, but the present invention is not limited to these examples.

実施例1:軟膏剤
以下の組成と割合に従って原料を取った。まずは、オリーブ油を凝結させてから高速遠心して不飽和脂肪酸を精製した。精製された不飽和脂肪酸を65g、リジン、トリプトファン、フェニルアラニン、メチオニン、スレオニン、イソロイシン、ロイシン、バリンの混合物を2g、精製した魚鱗コラーゲンペプチドを5g、塩化ナトリウムを0.9g、塩化カリウムを0.1g、ビタミンEを0.1g、ビタミンAを0.1g使用し、その中にプロポリスを25g、植物性香料を1.8g加えた。次いで、コラーゲン、アミノ酸及び無機塩を水に溶解させることで、水溶性ゲルマトリックスを得た。次いで、ビタミンを溶解させた不飽和脂肪酸中へ25gのプロポリスを加え、均一になるまで混合し、その後その中に上記水溶性ゲルマトリックスを徐々に加え、均一に乳化することにより、軟膏剤を得た。最終製品に仕上げて包装した。
Example 1: Ointment The raw material was taken according to the following composition and ratio. First, after condensing olive oil, the unsaturated fatty acid was purified by high-speed centrifugation. 65 g of purified unsaturated fatty acid, 2 g of a mixture of lysine, tryptophan, phenylalanine, methionine, threonine, isoleucine, leucine, and valine, 5 g of purified fish scale collagen peptide, 0.9 g of sodium chloride, and 0.1 g of potassium chloride In addition, 0.1 g of vitamin E and 0.1 g of vitamin A were used, and 25 g of propolis and 1.8 g of vegetable flavor were added thereto. Next, a water-soluble gel matrix was obtained by dissolving collagen, amino acids and inorganic salts in water. Next, 25 g of propolis is added to the unsaturated fatty acid in which the vitamin is dissolved, and the mixture is mixed until uniform, and then the water-soluble gel matrix is gradually added to the mixture and uniformly emulsified to obtain an ointment. It was. Finished product and packaged.

実施例2:軟膏剤
実施例1と同様の調製方法を用いた。ここで、以下の組成と割合に従って原料を取った。精製したオリーブ油を70g、魚鱗コラーゲンペプチドを0.1g、リジンなどの8種のアミノ酸の混合物を0.1g、ビタミンAを0.05g、ビタミンEを0.05g、NaClを0.05g、プロポリスを25g、及び植物性香料を4.65gとした。
Example 2: Ointment The same preparation method as in Example 1 was used. Here, the raw materials were taken according to the following composition and ratio. 70 g of purified olive oil, 0.1 g of fish scale collagen peptide, 0.1 g of a mixture of 8 amino acids such as lysine, 0.05 g of vitamin A, 0.05 g of vitamin E, 0.05 g of NaCl, propolis 25 g and 4.65 g of vegetable flavor were used.

実施例3:軟膏剤
実施例1と同様の調製方法を用いた。ここで、以下の組成と割合に従って原料を取った。精製した菜種油を65g、魚鱗コラーゲンペプチドを10g、リジンなどの8種のアミノ酸の混合物を6g、ビタミンAを3.5g、ビタミンEを3.5g、NaClを0.5g、KClを0.1g、プロポリスを10g、及び植物性香料を1.4gとした。
Example 3: Ointment The same preparation method as in Example 1 was used. Here, the raw materials were taken according to the following composition and ratio. 65 g of purified rapeseed oil, 10 g of fish scale collagen peptide, 6 g of a mixture of 8 amino acids such as lysine, 3.5 g of vitamin A, 3.5 g of vitamin E, 0.5 g of NaCl, 0.1 g of KCl, Propolis was 10 g and vegetable flavor was 1.4 g.

実施例4:軟膏剤
実施例1と同様の調製方法を用いた。ここで、以下の組成と割合に従って原料を取った。精製したひまわり油60g、魚鱗コラーゲンペプチドを5.5g、リジンなどの8種のアミノ酸の混合物を1.5g、ビタミンAを2.0g、ビタミンEを1.5g、NaClを0.4g、KClを0.1g、ワセリンを24g、及び植物性香料:5gとした。
Example 4: Ointment The same preparation method as in Example 1 was used. Here, the raw materials were taken according to the following composition and ratio. 60 g of purified sunflower oil, 5.5 g of fish scale collagen peptide, 1.5 g of a mixture of 8 amino acids such as lysine, 2.0 g of vitamin A, 1.5 g of vitamin E, 0.4 g of NaCl, KCl 0.1 g, 24 g of petrolatum, and 5 g of vegetable fragrance were used.

実施例5:軟膏剤
実施例1と同様の調製方法を用いた。ここで、以下の組成と割合に従って原料を取った。精製した茶油を55g、魚鱗コラーゲンペプチドを8g、リジンなどの8種のアミノ酸の混合物を3g、ビタミンAを3.0g、ビタミンEを2.0g、NaClを0.9g、KClを0.1g、ワセリンを25g、及び植物性香料を3gとした。
Example 5: Ointment The same preparation method as in Example 1 was used. Here, the raw materials were taken according to the following composition and ratio. 55 g of purified tea oil, 8 g of fish scale collagen peptide, 3 g of a mixture of 8 amino acids such as lysine, 3.0 g of vitamin A, 2.0 g of vitamin E, 0.9 g of NaCl, 0.1 g of KCl , 25 g of petroleum jelly and 3 g of vegetable flavor were used.

実施例6:軟膏剤
実施例1と同様の調製方法を用いた。ここで、以下の組成と割合に従って原料を取った。精製したオリーブ油を50g、魚鱗コラーゲンペプチドを10g、リジンなどの8種のアミノ酸の混合物を6g、ビタミンAを3.5g、ビタミンEを3.5g、NaClを0.9g、KClを0.1g、ワセリンを22g、及び植物性香料を4.0gとした。
Example 6: Ointment The same preparation method as in Example 1 was used. Here, the raw materials were taken according to the following composition and ratio. 50 g of purified olive oil, 10 g of fish scale collagen peptide, 6 g of a mixture of 8 amino acids such as lysine, 3.5 g of vitamin A, 3.5 g of vitamin E, 0.9 g of NaCl, 0.1 g of KCl, Vaseline was 22 g, and vegetable flavor was 4.0 g.

実施例7:液剤
以下の組成と割合に従って原料を取った。まずは、オリーブ油を凝結させてから高速遠心して不飽和脂肪酸を精製した。精製後の不飽和脂肪酸を80g、リジン、トリプトファン、フェニルアラニン、メチオニン、スレオニン、イソロイシン、ロイシン、バリンの混合物を6g、魚鱗コラーゲンペプチドを10g、塩化ナトリウムを0.9g、塩化カリウムを0.1g、ビタミンEを1.5g、ビタミンAを1.5g使用した。次いで、コラーゲン、アミノ酸及び無機塩を水に溶解させることで、水溶性ゲルマトリックスを得た。次いで、ビタミンを溶解させた不飽和脂肪酸中に上記水溶性ゲルマトリックスを徐々に加え、均一に乳化させることにより、液剤を得た。このように、最終製品に仕上げて包装した。
Example 7: Solution The raw material was taken according to the following composition and ratio. First, after condensing olive oil, the unsaturated fatty acid was purified by high-speed centrifugation. 80 g of purified unsaturated fatty acid, 6 g of lysine, tryptophan, phenylalanine, methionine, threonine, isoleucine, leucine, valine mixture, 10 g of fish scale collagen peptide, 0.9 g of sodium chloride, 0.1 g of potassium chloride, vitamin 1.5 g of E and 1.5 g of vitamin A were used. Next, a water-soluble gel matrix was obtained by dissolving collagen, amino acids and inorganic salts in water. Subsequently, the water-soluble gel matrix was gradually added to the unsaturated fatty acid in which the vitamin was dissolved, and the mixture was uniformly emulsified to obtain a solution. Thus, the final product was finished and packaged.

実施例8:マスク
実施例1又は実施例7に記載の製品を単層の薄膜状の下地に塗布し、マスクに加工した後パッケージする。上記薄膜状下地は純綿、不織布又は合成繊維材料を用いる。
Example 8: Mask The product described in Example 1 or Example 7 is applied to a single-layer thin film substrate, processed into a mask, and then packaged. The thin film base is made of pure cotton, non-woven fabric or synthetic fiber material.

臨床実験例
本発明に係る製剤は、臨床に大きく応用され、効果的なフィードバックが得られた。即ち、臨床応用において、皮膚血液循環の改善、肌の免疫力と皮膚の栄養状態の強化、角質層の柔軟化、顔色の改善及び色素吸収の促進等の役割があり、毛穴を閉塞する角質層、重金属及び化学汚染物の除去、輻射の防止、皮膚への栄養供給ができる。また、活性栄養物質と栄養成分に富み、すぐに皮膚に浸透し皮膚細胞に欠けた栄養を迅速に補充でき、即効性がある。また、毛穴を縮め、細胞再生を増強し、皮膚に必要な栄養を補充し、細胞自身の免疫力を向上させることができる。本発明に係る製剤を用いて皮膚病を治療した臨床観察実験は以下に示す。
Clinical Experimental Example The preparation according to the present invention was greatly applied to clinical practice, and effective feedback was obtained. That is, in clinical application, it has the role of improving skin blood circulation, strengthening skin immunity and skin nutrition, softening stratum corneum, improving facial color and promoting pigment absorption, and stratum corneum that blocks pores It can remove heavy metals and chemical contaminants, prevent radiation, and supply nutrients to the skin. In addition, it is rich in active nutrients and nutrients, can quickly penetrate the skin and quickly replenish the nutrients lacking skin cells, and has immediate effect. In addition, the pores can be shortened, the cell regeneration can be enhanced, the nutrients necessary for the skin can be supplemented, and the immunity of the cells themselves can be improved. A clinical observation experiment in which skin diseases are treated using the preparation according to the present invention is shown below.

臨床観察実験一:乾癬の治療。   Clinical observational experiment 1: Treatment of psoriasis.

1、基本資料:
乾癬患者合計40例で、全病例をランダムに対照群と実験群に分け、1群は20例である。
1. Basic materials:
There are a total of 40 psoriasis patients, and all cases are randomly divided into a control group and an experimental group, and one group is 20 cases.

2、実験方法:
対照群患者の皮膚に、臨床常用のグルココルチコイドを昼夜各1回塗布し、7日間後、アジスロマイシン軟膏(azithromycin cream)の塗布を始め、それを1日3回行った。実験群患者の発症部位に、本発明の実施例1の軟膏剤を昼夜各1回塗布した。そして、実験開始の7日目、1ヶ月目、2ヶ月目に、2群の患者の皮膚の回復状況をそれぞれ観察した。
2. Experimental method:
A clinically used glucocorticoid was applied once a day and night to the skin of a control group patient, and after 7 days, azithromycin cream was applied three times a day. The ointment of Example 1 of the present invention was applied once each day and night to the onset sites of the experimental group patients. Then, on the seventh day, the first month, and the second month after the start of the experiment, the skin recovery conditions of the two groups of patients were observed.

3、治療効果:
対照群患者は、グルココルチコイドを使用した7日間後、皮膚がよくなり滑らかとなりはじめた。7日間後、グルココルチコイドの代わりにアジスロマイシン軟膏を使用し、3週間治療し続けた。治療開始の1ヶ月後、乾癬の一部の鱗屑が柔らかになり剥がれ始めた。治療開始の2ヶ月後、治療開始の1ヶ月の時と比べて、治療状況はあまり差がなく、患者の乾癬が改善したが、完治した患者がいない。
3. Treatment effect:
The control group patients began to feel better and smoother after 7 days of using glucocorticoids. After 7 days, azithromycin ointment was used instead of glucocorticoid and treatment was continued for 3 weeks. One month after the start of treatment, some scales of psoriasis began to soften and peel off. Two months after the start of treatment, the treatment situation is not much different compared to one month after the start of treatment, and the patient's psoriasis improved, but no patients were completely cured.

実験群患者は、本発明に係る製剤を使用した7日間後、皮膚がよくなり滑らかなになりはじめたが、対照群の方がより効果的である。使用開始の1ヶ月後、乾癬の一部の鱗屑が柔らかになり剥がれ始めたが、対照群と比べてあまり差がない。使用開始の2ヶ月後、20名患者中で、18名患者は殆ど完治し、1名患者は大きく改善し、1名患者は改善しなかった。   Patients in the experimental group began to feel better and smoother after 7 days using the formulation according to the present invention, but the control group is more effective. One month after the start of use, some scales of psoriasis began to soften and peel off, but there is not much difference compared to the control group. Two months after the start of use, of the 20 patients, 18 patients were almost completely cured, one patient improved greatly, and one patient did not improve.

使用開始初期に、本発明に係る製剤の乾癬に対する治療効果は、ホルモンと抗生物質に比べて、即効性が低いが、使用開始の2ヶ月後、本発明に係る製剤は臨床通用のホルモンと抗生物質類医薬品より、乾癬に対する治療効果がよいことが、臨床的に実証された。以上の結果から、本発明に係る製剤は乾癬等皮膚疾病への治療、皮膚再生の時間の短縮、副作用の低減に有効であることが分かった。   At the beginning of use, the therapeutic effect of the preparation according to the present invention on psoriasis is less immediate than that of hormones and antibiotics, but two months after the start of use, the preparation according to the present invention has clinically effective hormones and antibiotics. It has been clinically demonstrated that it has a better therapeutic effect on psoriasis than substance drugs. From the above results, it was found that the preparation according to the present invention is effective in treating skin diseases such as psoriasis, shortening the time for skin regeneration, and reducing side effects.

臨床観察実験二:にきびの治療。   Clinical observation experiment 2: Treatment of acne.

1、基本資料:
にきび患者合計50例で、全病例をランダムに対照群と実験群に分け、1群は25例である。
1. Basic materials:
There are a total of 50 acne patients, and all cases are randomly divided into a control group and an experimental group, and one group is 25 cases.

2、実験方法:
対照群患者に、臨床常用の薬であるイソトレチノインを1日2回経口投与し、実験群患者の発症部位に、本発明の軟膏剤を昼夜各1回塗布した。そして、実験開始の2日目、7日目、2週間目に、2群の患者の皮膚の回復状況をそれぞれ観察した。
2. Experimental method:
The control group patients were orally administered with isotretinoin, which is a commonly used drug, twice a day, and the ointment of the present invention was applied once a day and night to the onset site of the experimental group patients. Then, on the second day, the seventh day, and the second week from the start of the experiment, the skin recovery status of the two groups of patients was observed.

3、治療効果:
対照群患者には、イソトレチノインを経口投与した2日間後、皮膚が良くなった。経口投与した7日間後、以前より皮膚の改善にあまり効果がなかった。経口投与した2週間後、治療開始の1週間の時と比べて、治療状況はあまり差がなく、患者のにきびが改善したが、完治した患者がいない。
3. Treatment effect:
The control group patients had improved skin 2 days after oral administration of isotretinoin. Seven days after oral administration, the skin was less effective than before. Two weeks after oral administration, the treatment status is not much different from that of one week after the start of treatment, and the patient's acne improved, but no patient was completely cured.

実験群患者には、本発明に係る製剤を使用した2日間後、皮膚がよくなり滑らかなになりはじめ、1日間前にできたにきび膿疱が消褪しはじめたので、対照群より優れた。使用した7日間後、9名患者はにきび膿疱が完全に消失し、13名患者は一部の膿疱が消失し、3名患者は大きく改善しなかったので、対照群よりも著しく優れた。使用した2週間後、25名患者中で、22名患者は完治し、2名患者は大きく改善し、1名患者は改善しなかった。   The patients in the experimental group were superior to the control group since the skin started to become smooth and smooth after 2 days of using the preparation according to the present invention, and the acne pustules formed one day ago began to disappear. Seven days after use, 9 patients were completely better than the control group because acne pustules disappeared completely, 13 patients lost some pustules and 3 patients did not improve significantly. Two weeks after use, of 25 patients, 22 patients were completely cured, 2 patients improved significantly, and 1 patient did not improve.

本発明に係る製剤を使用した2日間後、治療効果は対照群より優れ、使用した7日間後、治療効果は対照群より著しく優れ、本発明に係る製剤を使用した2週間後、本発明に係る製剤は対照群に比べて、にきびに対する治療効果が顕著であることが、臨床的に実証された。上記の結果から、本発明に係る製剤を使用してにきびを治療すると、顕著的に皮膚再生の時間を短縮し副作用を低減することができることが分かった。   Two days after using the preparation according to the present invention, the therapeutic effect is superior to the control group, seven days after use, the therapeutic effect is remarkably superior to the control group, and two weeks after using the preparation according to the present invention, It has been clinically demonstrated that such a preparation has a significant therapeutic effect on acne compared to the control group. From the above results, it was found that when acne is treated using the preparation according to the present invention, skin regeneration time can be significantly shortened and side effects can be reduced.

なお、以下、典型的な臨床ケースを示して具体的にその効果を説明する、
臨床ケース1:李××、男、61歳、年中運転しているので、足部に鶏眼ができたが、本製品を使用した二週間後、鶏眼が柔軟となり始め、二ヵ月後剥がれて完治した。同時に、本製品を使用して老人斑を治療し、一ヵ月後、大部分の老人斑が浅くなり、一部が消えた。
In the following, typical clinical cases will be shown and their effects will be specifically explained.
Clinical Case 1: Lee XX, male, 61 years old, driving all year round so that the eyes are visible, but two weeks after using this product, the eyes start to become flexible and two months later It peeled off and was completely cured. At the same time, this product was used to treat senile plaques. After one month, most of the senile plaques became shallow and some disappeared.

臨床ケース2:白××、男、60歳、若いころ力仕事していたので、足部のたこが厚く、二日ごとに角質層を取り除く必要があったが、本製品を使用した一週間後、角質層が柔軟となり、刀で角質層を除去する必要がなくなり、一ヵ月後、たこが薄くなり、普通の皮膚と同じになる同時に、足部の皮膚が平滑になり、ピンク色に変わった。   Clinical Case 2: White xx, male, 60 years old, working hard when young, thick foot octopus, needed to remove stratum corneum every two days, one week using this product After that, the stratum corneum becomes soft and it is no longer necessary to remove the stratum corneum with a sword. After one month, the octopus becomes thin and becomes the same as normal skin. At the same time, the skin of the foot becomes smooth and turns pink. It was.

臨床ケース3:常××、女、58歳、湿疹を患ったが、本製品を使用した一週間後完治した。   Clinical Case 3: Always xx, female, 58 years old, suffered from eczema, but was completely cured one week after using this product.

臨床ケース4:王××、女、21歳、にきびがひどかったが、本製品を使用して発症部位に薄く一日2−3回塗り、使用開始の二日後、新しくできたにきびの赤く腫れた部分は消褪し、使用開始の二週間後、長い前にできたにきびの赤く腫れた部分は消褪し、毛嚢内の膿球が消え、発症部位が滑らかになり、使用開始の一ヶ月後、残った色素が消えた。   Clinical Case 4: Wang xx, female, 21 years old, acne was severe, but using this product, thinly applied 2-3 times a day on the onset site, two days after the start of use, a new acne red swelling 2 weeks after the start of use, the red swollen part of the acne that was made long ago disappears, the pus bulb in the hair follicle disappears, the site of onset becomes smooth, and one month of start of use Later, the remaining pigment disappeared.

臨床ケース5:ゴ××、男、35歳、冬に乾癬ができ、薬を飲んだり注射を受けたりしても、改善もしなかったが、本製品を使用して発症部位に薄く一日2−3回塗り、即効に痒みを止め、使用開始の二週間後、鱗屑が剥がれて発症部位が滑らかになり、使用開始の一ヶ月後、残った赤いニュースキンと色素が沈着して消えた。   Clinical Case 5: Goxx, male, 35 years old, psoriasis in winter, did not improve even after taking medicines or receiving injections. -3 times, itch was stopped immediately, and after 2 weeks from the start of use, the scales were peeled off and the onset site became smooth, and one month after the start of use, the remaining red New Skin and pigment were deposited and disappeared.

臨床ケース6:尹××、男、36歳、爪囲炎を患ったが、本製品を使用した一ヶ月後、即効に改善した。   Clinical Case 6: Acupuncture xx, male, 36 years old, suffered from periodontitis, but improved immediately after one month of using this product.

以上の病例から、本発明の組成物及びそれを用いた製剤は、臨床通常の皮膚疾病への治療効果が優れたことが分かった。   From the above cases, it was found that the composition of the present invention and the preparation using the composition were excellent in the therapeutic effect on clinically normal skin diseases.

Claims (9)

にきびの治療用組成物であって、
前記組成物は、不飽和脂肪酸、コラーゲン、アミノ酸、ビタミン及び無機塩を含み、
前記組成物において、重量%で、前記不飽和脂肪酸の含有量が65%〜90%であり、前記コラーゲンの含有量が0.1%〜15%であり、前記アミノ酸の含有量が0.1%〜10%であり、前記ビタミンの含有量が0.1%〜10%であり、前記無機塩の含有量が0.05%〜1%であ
前記ビタミンとしてビタミンAを含む、
ことを特徴とするにきびの治療用組成物。
A composition for the treatment of acne ,
The composition comprises unsaturated fatty acids, collagen, amino acids, vitamins and inorganic salts;
In the composition, the unsaturated fatty acid content is 65% to 90%, the collagen content is 0.1% to 15%, and the amino acid content is 0.1% by weight. % is 10%, 0.1% to 10% content of the vitamin, Ri 0.05% to 1% der content of the inorganic salt,
Vitamin A is included as the vitamin,
A composition for the treatment of acne characterized by the above.
前記不飽和脂肪酸は、アラキドン酸、オレイン酸、リノレン酸、及びリノール酸からなる群から選ばれる一種以上であることを特徴とする請求項1に記載のにきびの治療用組成物。 The composition for treating acne according to claim 1, wherein the unsaturated fatty acid is at least one selected from the group consisting of arachidonic acid, oleic acid, linolenic acid, and linoleic acid. 前記アミノ酸は、グルタミン酸、リジン、トリプトファン、フェニルアラニン、メチオニン、スレオニン、イソロイシン、ロイシン、バリン、ヒスチジン、及びアルギニンからなる群から選ばれる一種以上であることを特徴とする請求項1に記載のにきびの治療用組成物。 The acne treatment according to claim 1, wherein the amino acid is one or more selected from the group consisting of glutamic acid, lysine, tryptophan, phenylalanine, methionine, threonine, isoleucine, leucine, valine, histidine, and arginine. Composition. 前記ビタミンとしてビタミンEをさらに含むことを特徴とする請求項1に記載のにきびの治療用組成物。 The composition for treating acne according to claim 1, further comprising vitamin E as the vitamin . 前記無機塩はナトリウム塩及び/又はカリウム塩であることを特徴とする請求項1に記載のにきびの治療用組成物。 The composition for treating acne according to claim 1, wherein the inorganic salt is a sodium salt and / or a potassium salt. 各成分の含有量は、重量%で、不飽和脂肪酸が65%〜70%、コラーゲンが0.1%〜10%、アミノ酸が0.1%〜6%、ビタミンが0.1%〜7%、無機塩が0.05%〜1%、賦形剤が10%〜25%、及び植物性香料が1%〜5%であり、
前記ビタミンとしてビタミンAを含むことを特徴とするにきびの治療用製剤。
The content of each component is% by weight, 65% to 70% of unsaturated fatty acid, 0.1% to 10% of collagen, 0.1% to 6% of amino acid, and 0.1% to 7% of vitamin. , inorganic salts 0.05% to 1%, excipient 10% to 25%, and Ri 1% to 5% der vegetable flavor,
A preparation for the treatment of acne , which comprises vitamin A as the vitamin .
前記ビタミンは、0.1%〜1%のビタミンEと0.1%〜1%のビタミンAを含むことを特徴とする請求項6に記載のにきびの治療用製剤。 The preparation for acne treatment according to claim 6, wherein the vitamin comprises 0.1% to 1% vitamin E and 0.1% to 1% vitamin A. 前記無機塩は、0.05%〜0.9%のナトリウム塩と0.05%〜0.1%のカリウム塩を含むことを特徴とする請求項6に記載のにきびの治療用製剤。 The preparation for treating acne according to claim 6, wherein the inorganic salt comprises 0.05% to 0.9% sodium salt and 0.05% to 0.1% potassium salt. 前記製剤の組成に従って原料を取るステップと、
コラーゲンおよび水溶性原料を溶解させて、水溶性ゲルマトリックスを得るステップと、
不飽和脂肪酸に賦形剤を加え、均一に混合させた後、他の原料を徐々に加え、均一に乳化させることにより、製剤を得るステップと、
最終製品に仕上げて包装するステップと、を含むことを特徴とする請求項6に記載のにきびの治療用製剤の調製方法。
Taking the raw material according to the composition of the formulation;
Dissolving collagen and a water-soluble raw material to obtain a water-soluble gel matrix;
Adding an excipient to the unsaturated fatty acid and mixing uniformly, then gradually adding other ingredients and uniformly emulsifying to obtain a formulation; and
The method for preparing a therapeutic formulation for acne according to claim 6, comprising finishing and packaging into a final product.
JP2012064489A 2011-03-22 2012-03-21 Composition for treating dermatosis, formulation using the same, and preparation method thereof Expired - Fee Related JP5622775B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201110068644.0 2011-03-22
CN201110068644.0A CN102688483B (en) 2011-03-22 2011-03-22 Composition for treating dermatosis, preparation containing composition and preparation method thereof

Publications (2)

Publication Number Publication Date
JP2012197276A JP2012197276A (en) 2012-10-18
JP5622775B2 true JP5622775B2 (en) 2014-11-12

Family

ID=46854326

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012064489A Expired - Fee Related JP5622775B2 (en) 2011-03-22 2012-03-21 Composition for treating dermatosis, formulation using the same, and preparation method thereof

Country Status (4)

Country Link
JP (1) JP5622775B2 (en)
KR (1) KR101445730B1 (en)
CN (1) CN102688483B (en)
HK (1) HK1161510A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104367992A (en) * 2014-10-20 2015-02-25 广西壮族自治区花红药业股份有限公司 New application of type I collagen in preparation of medicament for treating and/or preventing psoriasis
CN106902388A (en) * 2015-12-22 2017-06-30 上海邦中高分子材料有限公司 A kind of 3D printing biochargeable paper and its production and use
JP2019019101A (en) * 2017-07-20 2019-02-07 クラシエホームプロダクツ株式会社 Skin Cosmetic
JP7343885B2 (en) * 2017-07-20 2023-09-13 クラシエホームプロダクツ株式会社 skin cosmetics
CN108355130A (en) * 2018-05-22 2018-08-03 界首市菁华科技信息咨询服务有限公司 It is a kind of to treat psoriasic temperature sensitive type collagen composite antiphlogistic gel spray and preparation method thereof
CN114177348B (en) * 2021-12-14 2023-02-10 华北理工大学 Medical liquid dressing and preparation method and application thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU693312B2 (en) * 1995-01-18 1998-06-25 Taisho Pharmaceutical Co., Ltd. Remedy for dermatitis
AU7582398A (en) 1997-05-19 1998-12-11 Rosemarie Scivoletto Composition for treating skin conditions
DE19831798A1 (en) * 1998-07-15 2000-01-27 Mandorlo Investment Gmbh Luxem Microcirculation improving skin and tissue care or treatment composition, containing salts, aminoacids and peroxide, used as cosmetic, medicament or nutrient supplement
CU22693A1 (en) * 1999-02-22 2001-07-31 Ct De Histoterapia Placentaria COMPOSITION FOR THE TREATMENT OF PSORIASIS AND METHOD FOR OBTAINING
CN1270160A (en) * 1999-04-14 2000-10-18 李文光 Refined unsaturated polyfatty acid and calcium salt of unsaturated polyfatty acid as medicinal products and preparing process thereof and preparation
JP2002047123A (en) 2000-08-02 2002-02-12 Asahi Kasei Corp Perfumery
CN1357314A (en) * 2000-12-12 2002-07-10 长沙市海人生物科技有限公司 Bioactive hot-spring bath prepn
EP1635782A1 (en) 2003-05-24 2006-03-22 JUVENA (International) AG Tissue culture media used as a component of cosmetics
CN101168104B (en) 2007-08-21 2011-11-02 天津天大天久科技股份有限公司 Gas-liquid distributing device for large stuffing tower device
JP2010248148A (en) * 2009-04-17 2010-11-04 Rohto Pharmaceut Co Ltd Breakdown agent of advanced glycation end product

Also Published As

Publication number Publication date
JP2012197276A (en) 2012-10-18
CN102688483A (en) 2012-09-26
KR101445730B1 (en) 2014-10-01
KR20120107864A (en) 2012-10-04
CN102688483B (en) 2015-02-18
HK1161510A2 (en) 2012-07-27

Similar Documents

Publication Publication Date Title
JP5622775B2 (en) Composition for treating dermatosis, formulation using the same, and preparation method thereof
JP6495183B2 (en) Compositions and methods for treating surface wounds
US11058735B2 (en) Formulations containing pomegranate seed oil, rosa canina fruit oil and inula viscosa oleoresin or extract
PT1853303E (en) Stabilized compositions for topical administration and methods of making same
JP2011088930A (en) Carbon dioxide percutaneous and transmucosal absorption composition
EP0531495A1 (en) Therapeutic and cosmetic compositions for treatment of skin.
JP5643872B2 (en) Carbon dioxide transdermal / mucosal absorption composition
JP5164438B2 (en) Carbon dioxide transdermal / mucosal absorption composition
JP5699184B2 (en) Carbon dioxide transdermal / mucosal absorption composition
EP2692332B1 (en) Composition for the treatment of callus, corns and psoriasis
WO2016144196A1 (en) A pharmaceutical and/or cosmetic composition for treating skin diseases and damages, the process for preparing of the pharmaceutical and/or cosmetic composition and its use
WO2015168224A1 (en) Synergistic mixture of betamethasone and tranilast with a transdermal gel for scar treatment
CN112316108B (en) Compositions and methods for promoting and treating chronic wound healing
CN105982882B (en) A kind of externally applied drug and preparation process of optical active starting materials composition prescription therapeutic hemorrhoid
KR20220148853A (en) Formulations and uses thereof
KR101607229B1 (en) A composition for treating wound containing horse oil
CN113713000B (en) Main medicine component composition for treating sore carbuncle, burn, scald and acne, sustained and controlled release pharmaceutical preparation, and preparation method and application thereof
JP5993336B2 (en) Carbon dioxide transdermal / mucosal absorption composition
RU2500409C2 (en) Dermatological agent
KR20100111061A (en) Composition for wound healing
CN106581663A (en) Composition for treating hormone-dependent dermatitis
WO2007133641A1 (en) Enhanced protection against skin injury in humans
JP2013177461A (en) Composition for percutaneously and transmucosally absorbing carbon dioxide
RU2572705C1 (en) Mouthwash composition
WO2015031903A1 (en) Novel skin care formulation

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20130605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130605

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140724

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140801

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140902

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140922

R150 Certificate of patent or registration of utility model

Ref document number: 5622775

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees